When using the mean costs of LEH in a sensitivity analysis, the incremental costs per QALY gained were US$3600 for cataract surgery and US$4588 for RE/presbyopia correction.
Using the mean costs in the intervention and control arms, and the mean health outcomes in the control and intervention groups, the incremental cost per additional health outcome gained (outcomes a-e above) of the intervention group compared to control group will be calculated; results will be plotted on a cost-effectiveness plane.
Using the mean costs in each trial arm, and the mean health outcomes in each arm, the incremental cost per health outcome (a-e, above) of the intervention group compared to the control group will be calculated and results will be plotted on a cost-effectiveness plane.
To calculate the most likely cost per health check up, we used the mean cost of outpatient visits at four different health centers in Tanzania.
In this particular case, it may be preferable to use the mean cost and standard error from the Medicare records for use in modelling the larger study.
Therefore, we used the mean cost per patient per year of home adaptations made because of MS, which has previously been calculated in the European Community [ 25- 27, 29].
When we estimated costs using PPP, the mean cost per capita of IDSR for Eritrea was $0.87 and $0.06 for Mali (14 times larger).
Cost-effectiveness is often calculated using the mean difference in costs and effects, and is based on comparison between two or more possible treatment options.
Potential cost-savings were calculated from the actual and anticipated morbidity rates using the mean difference in total costs.
Using the mean value, estimates of the cost of treatment saved during the 'after' period are £30 900 (without trend) and £26 500 (with trend), and with the median value, £30 900 (without trend) and £26 700 (with trend).
